FY2029 EPS Estimates for Journey Medical Boosted by Analyst

Journey Medical Corporation (NASDAQ:DERM) – Equities researchers at B. Riley increased their FY2029 earnings estimates for Journey Medical in a research note issued to investors on Thursday, November 13th. B. Riley analyst M. Mamtani now expects that the company will earn $0.93 per share for the year, up from their previous estimate of $0.85. The consensus estimate for Journey Medical’s current full-year earnings is ($1.02) per share.

Journey Medical (NASDAQ:DERM) last announced its earnings results on Wednesday, November 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.01). Journey Medical had a negative net margin of 14.58% and a negative return on equity of 39.94%. The company had revenue of $17.63 million for the quarter, compared to the consensus estimate of $18.85 million.

A number of other research analysts have also recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Journey Medical in a research note on Wednesday, October 8th. Zacks Research upgraded Journey Medical from a “strong sell” rating to a “hold” rating in a research report on Monday, October 13th. Lake Street Capital boosted their target price on Journey Medical from $9.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, August 13th. Finally, HC Wainwright began coverage on shares of Journey Medical in a research report on Monday, August 25th. They set a “buy” rating and a $13.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $12.17.

Journey Medical Stock Performance

Journey Medical stock opened at $7.89 on Friday. Journey Medical has a fifty-two week low of $3.54 and a fifty-two week high of $9.40. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.95 and a current ratio of 1.42. The stock has a market cap of $207.59 million, a P/E ratio of -22.54 and a beta of 0.80. The firm’s fifty day moving average price is $7.65 and its 200-day moving average price is $7.32.

Hedge Funds Weigh In On Journey Medical

Large investors have recently bought and sold shares of the stock. Wasatch Advisors LP lifted its position in Journey Medical by 23.8% in the second quarter. Wasatch Advisors LP now owns 1,152,059 shares of the company’s stock valued at $8,272,000 after purchasing an additional 221,456 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Journey Medical by 130.7% in the second quarter. Geode Capital Management LLC now owns 262,353 shares of the company’s stock worth $1,884,000 after buying an additional 148,612 shares during the period. Sheets Smith Investment Management bought a new stake in Journey Medical during the 3rd quarter valued at $946,000. Essex Investment Management Co. LLC boosted its position in Journey Medical by 55.1% during the 3rd quarter. Essex Investment Management Co. LLC now owns 354,021 shares of the company’s stock valued at $2,521,000 after buying an additional 125,818 shares during the period. Finally, Vanguard Group Inc. grew its stake in shares of Journey Medical by 8.9% in the third quarter. Vanguard Group Inc. now owns 615,229 shares of the company’s stock worth $4,380,000 after purchasing an additional 50,241 shares during the last quarter. 7.25% of the stock is owned by hedge funds and other institutional investors.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.